GSK

GSK plc

Add to Watchlist

Advanced Chart

36.310

-0.16(-0.439%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

36.870

Open

36.800

VWAP

36.45

Vol

6.13M

Mkt Cap

74.13B

Low

36.160

Amount

223.59M

EV/EBITDA(TTM)

6.17

Total Shares

2.04B

68.48B

EV/OCF(TTM)

10.93

P/S(TTM)

1.83

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

7.88B

-0.09%

1.136

+1.93%

8.20B

+2.35%

1.326

+2.56%

8.42B

+3.73%

0.707

+21.99%

Estimates Revision

The market is revising Downward the revenue expectations for GSK plc (GSK) for FY2025, with the revenue forecasts being adjusted by -1.04% over the past three months. During the same period, the stock price has changed by -0.38%.

Revenue Estimates for FY2025

Revise Downward

-1.04%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-49.22%

In Past 3 Month

Stock Price

Go Down

-0.38%

In Past 3 Month

3 Analyst Rating

11.32% Upside

Wall Street analysts forecast GSK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 40.42 USD with a low forecast of 35.25 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

3 Hold

0 Sell

Hold

11.32% Upside

Current: 36.310

Low

35.25

Averages

40.42

High

45.00

11.32% Upside

Current: 36.310

Low

35.25

Averages

40.42

High

45.00

Morgan Stanley

Underweight

downgrade

2025-07-18

New

Reason

Morgan Stanley

Price Target

2025-07-18

New

downgrade

Underweight

Reason

Morgan Stanley lowered the firm's price target on GSK to 1,290 GBp from 1,355 GBp and keeps an Underweight rating on the shares. The firm updated the company's model for currency moves and reduced Blenrep sales ahead of the Q2 report. Morgan Stanley cut its peak Blenrep sales estimate to GBP 500M from BBP 1.4B citing the "low probability" of a U.S. approval.

Berenberg

Buy

Hold

downgrade

$1,600

2025-06-03

Reason

Berenberg

Price Target

$1,600

2025-06-03

downgrade

Buy

Hold

Reason

Leerink

Outperform -> Market Perform

downgrade

$47 -> $9

2025-05-14

Reason

Leerink

Price Target

$47 -> $9

2025-05-14

downgrade

Outperform -> Market Perform

Reason

Piper Sandler

Christopher Raymond

Overweight

downgrade

$16 -> $12

2025-05-14

Reason

Piper Sandler

Christopher Raymond

Price Target

$16 -> $12

2025-05-14

downgrade

Overweight

Reason

Piper Sandler analyst Christopher Raymond lowered the firm's price target on iTeos Therapeutics to $12 from $16 and keeps an Overweight rating on the shares. The firm notes belrestotug + dostarlimab failed to meet pre-specified PFS in the GALAXIES Lung-201 study and showed insufficient ORR in the H&N-202 study. iTeos (ITOS) and GSK (GSK) are discontinuing the belrestotug program including the Phase III Lung-301 trial, and evaluating strategic alternatives.

JPMorgan

Overweight

Neutral

downgrade

$15 -> $8

2025-05-13

Reason

JPMorgan

Price Target

$15 -> $8

2025-05-13

downgrade

Overweight

Neutral

Reason

Jefferies

Peter Welford

Strong Buy

Hold

Downgrades

n/a

2024-11-12

Reason

Jefferies

Peter Welford

Price Target

n/a

2024-11-12

Downgrades

Strong Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for GSK plc (GSK.N) is 8.06, compared to its 5-year average forward P/E of 10.72. For a more detailed relative valuation and DCF analysis to assess GSK plc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

10.72

Current PE

8.06

Overvalued PE

13.89

Undervalued PE

7.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

8.36

Current EV/EBITDA

6.18

Overvalued EV/EBITDA

10.17

Undervalued EV/EBITDA

6.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.08

Current PS

1.68

Overvalued PS

2.42

Undervalued PS

1.74

Financials

Annual

Quarterly

FY2025Q1

YoY :

+1.33%

9.46B

Total Revenue

FY2025Q1

YoY :

+2.22%

2.91B

Operating Profit

FY2025Q1

YoY :

+62.57%

2.23B

Net Income after Tax

FY2025Q1

YoY :

+53.12%

0.49

EPS - Diluted

FY2025Q1

YoY :

+79.78%

857.29M

Free Cash Flow

FY2025Q1

YoY :

+0.55%

74.40

Gross Profit Margin - %

FY2025Q1

YoY :

-30.27%

10.78

FCF Margin - %

FY2025Q1

YoY :

+60.63%

23.58

Net Margin - %

FY2025Q1

YoY :

-28.16%

11.61

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

16.5M

USD

Months

0-12

22.3M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

2.7M

Volume

3-6

Months

2.8M

Volume

6-9

Months

16.1M

Volume

0-12

Months

3.4M

Volume

Bought

0-3

6.3M

Volume

Months

3-6

12.9M

Volume

Months

6-9

7.0M

Volume

Months

0-12

5.8M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

16.0K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

8.0K

USD

Months

6-9

8.0K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

16.5M

USD

Months

0-12

22.3M

USD

Months

GSK News & Events

Events Timeline

2025-07-17 (ET)

2025-07-17

17:05:39

GSK provides update on US FDA advisory committee review of Blenrep

2025-07-17

07:14:17

GSK announces FDA approval of prefilled syringe presentation of Shingrix

2025-07-17

06:27:44

GSK announces US FDA approved prefilled syringe presentation of SHINGRIX

News

9.0

07-18NASDAQ.COM

PinnedGSK Plc: Confident In Benefit/risk Profile Of Blenrep

9.0

07-18Benzinga

PinnedGSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

9.0

07-17WSJ

PinnedFDA Committee Votes Against GSK Blood Cancer Drug Blenrep

People Also Watch

Becton Dickinson and Co

Republic Services Inc

FAQ

What is GSK plc (GSK) stock price today?

The current price of GSK is 36.31 USD — it has decreased -0.44 % in the last trading day.

GSK

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

GSK News & Events

Events Timeline

News

People Also Watch

FAQ

What is GSK plc (GSK) stock price today?

What is GSK plc (GSK)'s business?

What is the price predicton of GSK Stock?

What is GSK plc (GSK)'s revenue for the last quarter?

What is GSK plc (GSK)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for GSK plc (GSK)'s fundamentals?

How many employees does GSK plc (GSK). have?

What is GSK plc (GSK) market cap?